Ocugen, Inc. (OCGN) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Malvern, PA, アメリカ. 現CEOは Shankar Musunuri.
OCGN を有する IPO日 2014-12-03, 95 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $639.4M.
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
